• Mashup Score: 0

    Michael Morris, MD joins Charles Ryan, MD in a discussion on the United States (US) FDA Approval of PYLARIFY®, an F 18-labeled prostate-specific membrane antigen (PSMA) targeted positron emission tomography (PET) imaging agent. The F 18 tracer went through two qualifying clinical trials the CONDOR trial and then OSPREY trial. This is the first time a national commercial approval will render…

    Tweet Tweets with this article
    • PYLARIFY®, F 18-labeled PSMA Targeted PET @US_FDA Approval. @morr316 @sloan_kettering joins @charlesryanmd @UMNCancer to discuss the details of this imaging agent! #WatchNow on UroToday > https://t.co/YbhdLj0Lql @Progenics #Lantheus #PSMAPET #ProstateCancer #Imaging https://t.co/6hsuFNrOnm

  • Mashup Score: 0

    artificial intelligence platform developed to assist in standardized quantification of PSMA PET/CT scans, PYLARIFY AI, precision oncology, prostate cancer metastases.

    Tweet Tweets with this article
    • #Lantheus announces #PYLARIFY AI™ is now commercially available in the #UnitedStates! PYLARIFY AI has demonstrated improved consistency, accuracy, and efficiency in quantitative assessment of PSMA PET/CT. #ReadNow details on UroToday > https://t.co/GUJJUw0Jve https://t.co/s2Ul56x0sm

  • Mashup Score: 1
    PYLARIFY® - 3 year(s) ago

    Learn about PYLARIFY®.

    Tweet Tweets with this article
    • Amazing to see the rapid implementation and access to #Pylarify PSMA imaging for prostate cancer at @MolecularWCM. @ASTRO_org @AmerUrological @UroOnc @ASCO @Progenics #Lantheus https://t.co/2UkPAkK7Jr https://t.co/YbKFFNHPb3

  • Mashup Score: 0

    Michael Morris, MD joins Charles Ryan, MD in a discussion on the United States (US) FDA Approval of PYLARIFY®, an F 18-labeled prostate-specific membrane antigen (PSMA) targeted positron emission tomography (PET) imaging agent. The F 18 tracer went through two qualifying clinical trials the CONDOR trial and then OSPREY trial. This is the first time a national commercial approval will render…

    Tweet Tweets with this article
    • PYLARIFY®, F 18-labeled PSMA Targeted PET Approved! @morr316 @sloan_kettering joins @charlesryanmd @UMNCancer to discuss the details of this imaging agent! #WatchNow on UroToday > https://t.co/YbhdLj0Lql @Progenics #Lantheus #PSMAPET #ProstateCancer #Imaging @US_FDA https://t.co/5KGTqz9uV3

  • Mashup Score: 5

    Michael Morris, MD joins Charles Ryan, MD in a discussion on the United States (US) FDA Approval of PYLARIFY®, an F 18-labeled prostate-specific membrane antigen (PSMA) targeted positron emission tomography (PET) imaging agent. The F 18 tracer went through two qualifying clinical trials the CONDOR trial and then OSPREY trial. This is the first time a national commercial approval will render…

    Tweet Tweets with this article
    • PYLARIFY®, F 18-labeled PSMA Targeted PET gains @US_FDA Approval! @morr316 @sloan_kettering joins @charlesryanmd @UMNCancer to discuss the details! #WatchNow on UroToday > https://t.co/YbhdLj0Lql @Progenics #Lantheus #PSMAPET #ProstateCancer #Imaging https://t.co/EbRTK9vGan

  • Mashup Score: 7

    Lantheus Medical Imaging has received approval from the U.S. Food and Drug Administration (FDA) for Pylarify (F-18 DCFPyL), a PET radiopharmaceutical designed to target prostate-specific membrane antigen.

    Tweet Tweets with this article
    • #Lantheus has received FDA approval for Pylarify (F-18 DCFPyL), a PET radiopharmaceutical designed to target PSMA expressed by prostate cancers. https://t.co/s0hcjw0o2v #radiology #NucMed https://t.co/2MCHSXQ750